News|Articles|January 1, 2002

Infliximab and etanercept largely comparable in two real-world rheumatoid arthritis studies

Two new real-world comparisons of the tumor necrosis factor (TNF) blockers infliximab (Remicade) and etanercept (Enbrel) show that the two agents are highly comparable treatments for rheumatoid arthritis


Related to this article

Stafeeva-stock@adobe.com
Pharmacy benefit managers are moving beyond formulary access to provide support programs for women's health. Here's how three PBMs — Judi Health, LucyRx and RxPreferred — are putting that strategy into practice.